About Kamui Pharma
Kamui Pharma is a company based in Asahikawa (Japan) founded in 2018. Kamui Pharma has raised $96.26 million across 2 funding rounds from investors including Cyberdyne, DG Ventures and Mitsubishi UFJ Capital. Kamui Pharma operates in a competitive market with competitors including Aclaris Therapeutics, Novozymes, Phathom Pharmaceuticals, Protagonist Therapeutics and Seed, among others.
- Headquarter Asahikawa, Japan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$96.26 M (USD)
in 2 rounds
-
Latest Funding Round
$96.26 M (USD), Series B
Jul 26, 2022
-
Investors
Cyberdyne
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Kamui Pharma
Kamui Pharma has successfully raised a total of $96.26M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $96.26 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kamui Pharma
Kamui Pharma has secured backing from 5 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Cyberdyne, DG Ventures and Mitsubishi UFJ Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
DG Ventures is engaged in investing in startup companies.
|
Locked | Locked | Locked | |
|
Venture capital is invested in AI, energy, and various sectors.
|
Locked | Locked | Locked | |
|
Venture capital investments are made in emerging Japanese companies.
|
Locked | Locked | Locked |
Investor details for Kamui Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kamui Pharma
Investment portfolio details for Kamui Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kamui Pharma
Detailed financials for Kamui Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kamui Pharma Comparisons
Peer comparison for Kamui Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kamui Pharma
Kamui Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Novozymes, Phathom Pharmaceuticals, Protagonist Therapeutics and Seed, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Biosolutions and enzymes are developed for biotechnology applications across industries.
|
|
| Locked | Locked | Locked |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals.
|
|
| Locked | Locked | Locked |
Oral peptide therapeutics are developed for gastrointestinal diseases.
|
|
| Locked | Locked | Locked |
Synbiotics are developed for simulating the gut microbiome.
|
|
| Locked | Locked | Locked |
Microbiome therapeutics are developed to address diverse diseases.
|
Detailed competitors of Kamui Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kamui Pharma
Complete news archive for Kamui Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kamui Pharma
Kamui Pharma was founded in 2018.
Kamui Pharma is headquartered in Asahikawa, Japan. It is registered at Asahikawa, Hokkaido, Japan.
Kamui Pharma is a funded company, having raised a total of $96.26M across 2 funding rounds to date.
Kamui Pharma was founded in 2018 in Asahikawa, Japan, within the biotechnology sector. Probiotic medicines targeted at gastrointestinal diseases are developed, with a focus on inflammatory bowel disease (IBD). Physiologically active substances derived from probiotics, including poly P from Lactobacillus Brevis, are utilized for treatment purposes. Beneficial functions of these substances have been identified through research operations conducted in the region.
Kamui Pharma's top competitors include Phathom Pharmaceuticals, Novozymes and Aclaris Therapeutics.
Kamui Pharma has 5 investors. Key investors include Cyberdyne, DG Ventures, Mitsubishi UFJ Capital, Hokkaido Venture Capital, and Katsutoshi Hirose.